CV vs BFLY vs NEOG Stock Comparison

CapsoVision, Butterfly Network and Neogen Prices as of Oct 26, 2026 Peers: Industry group
CV CapsoVision, Inc
$6.89 +3.6% 1M +40.6% 1Y
Market cap
$337.08M
P/E
–
Revenue (TTM)
$14.41M
Div. yield
–
Diagnostic Equipment Healthcare
BFLY Butterfly Network, Inc.
$6.65 -29.2% 1M +198.2% 1Y
Market cap
$1.93B
P/E
–
Revenue (TTM)
$112.15M
Div. yield
–
Diagnostic Equipment Healthcare
3 wins
NEOG Neogen Corp
$12.21 -11.3% 1M +97.3% 1Y
Market cap
$2.72B
P/E
–
Revenue (TTM)
$883.99M
Div. yield
–
Diagnostic Equipment Healthcare
4 wins

Head to Head

7 decided of 12

Neogen leads on 4 of the 12 questions below (Neogen 4, Butterfly Network 3). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionCVBFLYNEOGLeader
Larger companyMarket capitalisation $337.08M $1.93B $2.72B NEOG
Cheaper on earningsLower P/E, profitable companies only -12.3x -25.8x -48.5x –
Cheaper on forward earningsLower price / next fiscal year consensus EPS — — 38.2x –
Faster revenue growthRevenue growth, trailing twelve months +14.6% +28.1% -0.3% BFLY
More profitableNet margin, trailing twelve months -190.2% -66.7% -6.3% NEOG
Better return on capitalReturn on invested capital — — -0.2% –
Less leveragedLower net debt / EBITDA — — 5.4x –
Higher dividend yieldTrailing dividend yield 0.00% 0.00% 0.00% –
Better 1-year returnPrice return, last 12 months +40.6% +198.2% +97.3% BFLY
Better 5-year returnAnnualised price return, 5 years — -8.0%/yr -21.6%/yr BFLY
Less volatileAnnualised volatility, 1 year 96.1% 114.6% 55.7% NEOG
Higher overall scoreMean of the five percentile scores vs peers 36/100 44/100 57/100 NEOG

Percentile Scorecard

CVBFLYNEOG

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisCVBFLYNEOG
Valuation 5 #217 of 228 29 #163 of 228 73 #63 of 228
Growth 42 #128 of 221 68 #72 of 221 49 #114 of 221
Profitability 23 #161 of 208 31 #143 of 208 61 #81 of 208
Financial Health 76 #59 of 239 60 #96 of 239 46 #129 of 239
Shareholder Returns – 35 #90 of 137 57 #59 of 137
Overall 36 44 57
  • CV ranked among 248 companies in Medical Devices and Diagnostics
  • BFLY ranked among 248 companies in Medical Devices and Diagnostics
  • NEOG ranked among 248 companies in Medical Devices and Diagnostics

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodCVBFLYNEOGSPY
1 month +3.6%-29.2%-11.3% -0.8%
3 months +4.2%-6.2%+30.7% +3.5%
6 months +8.2%+21.4%+29.2% +7.0%
Year to date -35.5%+75.0%+74.7% +12.2%
1 year +40.6%+198.2%+97.3% +13.0%
3 years —+741.8%-20.3% +86.3%
3 years, per year —+103.5%-7.3% +23.1%
5 years —-34.2%-70.3% +68.6%
5 years, per year —-8.0%-21.6% +11.0%
10 years ——-36.4% +258.0%
10 years, per year ——-4.4% +13.6%

Risk

MeasureCVBFLYNEOGSPY
Volatility, 1Y 96.1%114.6%55.7% 12.7%
Downside volatility, 1Y 89.7%91.7%46.5% 12.7%
Beta vs S&P 500, 1Y 0.622.971.44 1.00
Return / volatility, 1Y 0.421.731.75 1.02
Max drawdown, 5Y -67.8%-93.4%-90.6% -25.4%
From 52-week high -52.2%-33.1%-12.7% -1.8%
52-week high $14.42$9.94$13.98 $779.14
52-week low $4.59$1.97$5.41 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleCVBFLYNEOG
P/E now vs peer median -12.5xmedian 30.6x -23.3xmedian 30.6x -47.5xmedian 30.6x
P/S now vs peer median 23.9xmedian 3.0x 14.1xmedian 3.0x 3.0xmedian 3.0x
EV/EBITDA now vs peer median -12.5xmedian 17.5x -20.2xmedian 17.5x 29.5xmedian 17.5x
P/FCF now vs peer median —median 23.3x -56.4xmedian 23.3x 53.5xmedian 23.3x
P/B now vs peer median 26.2xmedian 2.4x 8.4xmedian 2.4x 1.3xmedian 2.4x
PEG now vs peer median —median 0.87 -0.86median 0.87 1.69median 0.87

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsCVBFLYNEOG
Revenue $14.41M $112.15M $883.99M
Gross profit $7.55M $59.04M $418.98M
Operating income -$27.71M -$79.38M -$7.38M
Net income -$27.42M -$74.85M -$56.10M
Free cash flow – -$28.04M $49.80M
R&D $20.51M $38.10M $19.76M
EPS (diluted) $-0.55 $-0.29 $-0.26
Cash & equivalents – $124.66M $172.00M
Total debt – – $774.20M
Shares (diluted) 49.94M 262.10M 218.10M
Enterprise value $337.08M $1.38B $2.06B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricCVBFLYNEOG
P/E -12.5x -23.3x -47.5x
P/FCF – -56.4x 53.5x
P/Operating cash flow – -65.9x 31.2x
P/S 23.9x 14.1x 3.0x
P/B 26.2x 8.4x 1.3x
P/Tangible book 26.2x 8.7x 3.4x
EV/EBITDA -12.5x -20.2x 29.5x
EV/EBIT -12.4x -18.4x -443.0x
EV/Revenue 23.9x 13.0x 3.7x
EV/FCF – -52.0x 65.6x
EV/Operating cash flow – -60.7x 38.3x
PEG (3Y EPS CAGR) – -0.86 1.69

Growth

14 metrics
MetricCVBFLYNEOG
Revenue growth (1Y) 14.6% 28.1% -0.3%
Revenue CAGR (3Y) – 15.6% -1.3%
Gross profit growth (1Y) 11.1% 8.8% 1.8%
Gross profit CAGR (3Y) – 13.3% -3.1%
Operating income growth (1Y) -36.1% -14.8% 99.3%
Operating income CAGR (3Y) – 21.1% -29.0%
Net income growth (1Y) -34.9% -19.1% 94.6%
Net income CAGR (3Y) – 20.8% -28.3%
EPS growth (1Y) 93.8% -12.9% 94.6%
EPS CAGR (3Y) – 27.0% -28.0%
Operating cash flow growth (1Y) – 19.6% -1.9%
Operating cash flow CAGR (3Y) – 44.5% 2.9%
Free cash flow growth (1Y) – 12.2% 1,631%
Free cash flow CAGR (3Y) – 42.8% 126.1%

Profitability

14 metrics
MetricCVBFLYNEOG
Gross margin 52.4% 52.6% 47.4%
EBITDA margin -190.7% -64.4% 12.5%
Operating margin -192.3% -70.8% -0.8%
Pretax margin -190.1% -66.7% -7.7%
Net margin -190.2% -66.7% -6.3%
FCF margin – -25.0% 5.6%
Operating cash flow margin – -21.4% 9.6%
Return on equity -207.5% -39.3% -2.7%
Return on assets -149.3% -26.3% -1.7%
Return on invested capital – – -0.2%
Return on capital employed -209.8% -35.1% -0.2%
Asset turnover 0.8x 0.4x 0.3x
Cash conversion (OCF / net income) – 0.3x -1.5x
Stock comp / revenue – 21.3% 1.3%

Financial Health

11 metrics
MetricCVBFLYNEOG
Debt / assets – – 23.4%
Debt / equity – – 0.4x
Net debt / EBITDA – – 5.4x
Debt / FCF – – 15.5x
Liabilities / assets 29.1% 33.1% 36.8%
Equity / assets 70.9% 66.9% 63.2%
Interest coverage – -59.4x –
Current ratio 3.4x 4.1x 3.9x
Quick ratio – 2.7x 2.1x
Cash ratio – 2.1x 1.2x
Altman Z-score 22.08 5.90 1.50

Shareholder Returns

7 metrics
MetricCVBFLYNEOG
Dividend yield – – –
Net buyback yield – -0.5% -0.1%
Shareholder yield 0.0% -0.5% -0.1%
Payout ratio (earnings) – – –
Payout ratio (FCF) – – –
Dividend growth (1Y) – – –
Dividend CAGR (3Y) – – –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusCVBFLYNEOG
Forward P/E – – 38.2xFY2026
EPS, next fiscal year $-0.58FY2026 $-0.10FY2026 $0.32FY2026
EPS growth, next FY – – 0.0%FY2026
EPS growth, the year after – – +31.3%
Revenue, next fiscal year $13.91MFY2026 $114.50MFY2026 $847.28MFY2026
Revenue growth, next FY +2.7%FY2026 +17.3%FY2026 -2.7%FY2026
Revenue growth, the year after +46.0% +26.0% -1.5%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersCVBFLYNEOG
Held by institutions 10.2% 59.9% 100.0%
Institutions holding 50 245 315
Change in shares held, QoQ +27.6% +13.9% +1.6%
Institutions buying 36 143 151
Institutions selling 8 59 106
Buyers to sellers 4.50 2.42 1.42

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

CVBFLYNEOG
CV 1.00 0.07 0.04
BFLY 0.07 1.00 0.25
NEOG 0.04 0.25 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, CV, BFLY and NEOG?

Neogen (NEOG) is the largest by market capitalisation: CapsoVision (CV) $337.08M, Butterfly Network (BFLY) $1.93B, Neogen (NEOG) $2.72B.

Which company is growing faster?

Butterfly Network (BFLY) grew revenue fastest over the trailing twelve months: CapsoVision (CV) +14.6%, Butterfly Network (BFLY) +28.1%, Neogen (NEOG) -0.3%.

Which company is more profitable?

Neogen (NEOG) has the highest net margin (CapsoVision (CV) -190.2%, Butterfly Network (BFLY) -66.7%, Neogen (NEOG) -6.3%).

Which stock has performed better?

Over the past year Butterfly Network (BFLY) returned the most: CapsoVision (CV) +40.6%, Butterfly Network (BFLY) +198.2%, Neogen (NEOG) +97.3%. Over five years, Butterfly Network (BFLY) compounded fastest (Butterfly Network (BFLY) -8.0%/yr, Neogen (NEOG) -21.6%/yr). Returns are price only, before dividends.

Which stock is riskier?

By one-year price volatility, Neogen (NEOG) has been the steadiest (CapsoVision (CV) 96.1%, Butterfly Network (BFLY) 114.6%, Neogen (NEOG) 55.7%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, CV, BFLY and NEOG?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Neogen (NEOG) leads on 4. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.